Business

Annual Report and Notice of AGM

Annual Report and Notice of AGM.

Venture Life Group PlcApril 28, 20235
Annual Report and Notice of AGM

About this update from Venture Life Group Plc

28 April 2023   VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Company")   Annual Report & Notice of AGM   Further to the Group's results for the year ended 31 December 2022 published on 4 April 2023 (RNS: 2432V ) the Board of VLG confirms that the Annual General Meeting of Venture Life will be held on 22 May 2023 at 10.00am at the offices of Simmons & Simmons LLP, Citypoint, 1 Ropemaker Street, London EC2Y 9SS. Copies of the Company's Annual Report and Accounts for the year ended 31 December 2022 have been sent to shareholders and are available to be viewed on the Venture Life website: www.venture-life.com   For further information, please contact:   Venture Life Group PLC                                                                                                    +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer   Cenkos Securities plc (Nomad and Joint Broker)                                                   +44 (0) 20 7397 8900 Stephen Keys / Camilla Hume (Corporate Finance) Russell Kerr / Michael Johnson (Sales)   Singer Capital Markets (Joint Broker) Shaun Dobson / Alaina Wong  (Corporate Finance)                                            +44 (0) 20 74963000 Jonathan Dighe (Sales)   About Venture Life ( www.venture-life.com ) Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.  Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.  

View stock analysis, news, and events for Venture Life Group Plc

More from Venture Life Group Plc

All Venture Life Group Plc news →